Bristol Myers Squibb (BMY) Long-Term Investments (2009 - 2026)

Bristol Myers Squibb (BMY) has 17 years of Long-Term Investments data on file, last reported at $366.0 million in Q1 2026.

• Long-Term Investments for Q1 2026 came in at $366.0 million, up 6.4% year-over-year; the trailing twelve-month figure through Mar 2026 was $366.0 million (up 6.4% YoY), and the FY2025 annual result was $396.0 million, up 23.75% from the prior year.
• Long-Term Investments eased to $366.0 million in Q1 2026 per BMY's latest filing, from $396.0 million in the prior quarter.
• Over five years, Long-Term Investments peaked at $406.0 million in Q3 2025 and troughed at $320.0 million in Q4 2024.
• A 4-year average of $359.0 million and a median of $360.5 million in 2023 frame the typical range for Long-Term Investments.
• The sharpest annual moves came in 2024 and 2025: Long-Term Investments decreased 12.09% in 2024, then increased 25.31% in 2025.
• A 4-year view of Long-Term Investments shows it stood at $364.0 million in 2023, then retreated by 12.09% to $320.0 million in 2024, then rose by 23.75% to $396.0 million in 2025, then slipped by 7.58% to $366.0 million in 2026.
• Business Quant data shows BMY's Long-Term Investments at $366.0 million in Q1 2026, $396.0 million in Q4 2025, and $406.0 million in Q3 2025.